Grifols (GRFS) Competitors $6.99 -0.01 (-0.14%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$7.25 +0.26 (+3.71%) As of 04/15/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. TEVA, ITCI, SMMT, GMAB, RDY, MRNA, VTRS, QGEN, ASND, and ROIVShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Grifols (NASDAQ:GRFS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends. Which has more volatility and risk, GRFS or TEVA? Grifols has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Does the MarketBeat Community prefer GRFS or TEVA? Teva Pharmaceutical Industries received 984 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 67.82% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.09% of users gave Grifols an outperform vote. CompanyUnderperformOutperformGrifolsOutperform Votes35056.09% Underperform Votes27443.91% Teva Pharmaceutical IndustriesOutperform Votes133467.82% Underperform Votes63332.18% Is GRFS or TEVA a better dividend stock? Grifols pays an annual dividend of $0.36 per share and has a dividend yield of 5.2%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 7.4%. Grifols pays out 30.8% of its earnings in the form of a dividend. Teva Pharmaceutical Industries pays out -69.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teva Pharmaceutical Industries is clearly the better dividend stock, given its higher yield and lower payout ratio. Do insiders & institutionals believe in GRFS or TEVA? 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is GRFS or TEVA more profitable? Grifols has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Teva Pharmaceutical Industries -9.91%42.46%6.65% Which has better valuation and earnings, GRFS or TEVA? Grifols has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.21B0.67$64.20M$1.175.97Teva Pharmaceutical Industries$16.54B0.93-$1.64B-$1.45-9.37 Do analysts recommend GRFS or TEVA? Teva Pharmaceutical Industries has a consensus target price of $23.43, indicating a potential upside of 72.46%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the media refer more to GRFS or TEVA? In the previous week, Teva Pharmaceutical Industries had 14 more articles in the media than Grifols. MarketBeat recorded 20 mentions for Teva Pharmaceutical Industries and 6 mentions for Grifols. Teva Pharmaceutical Industries' average media sentiment score of 1.08 beat Grifols' score of 0.93 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 15 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTeva Pharmaceutical Industries beats Grifols on 15 of the 21 factors compared between the two stocks. Remove Ads Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.81B$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E Ratio5.976.7921.7317.81Price / Sales0.67225.93379.1494.58Price / Cash9.5465.6738.1534.64Price / Book0.565.866.464.00Net Income$64.20M$141.86M$3.20B$247.23M7 Day Performance7.70%8.98%6.54%7.26%1 Month Performance-12.41%-12.65%-8.55%-6.26%1 Year Performance6.88%-11.99%10.33%-0.18% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.0949 of 5 stars$6.99-0.1%N/A+6.9%$4.81B$7.21B5.9726,300Gap DownTEVATeva Pharmaceutical Industries3.0326 of 5 stars$13.91+0.8%$23.43+68.5%+2.7%$15.77B$16.54B-9.5936,800Analyst DowngradeOptions VolumePositive NewsITCIIntra-Cellular Therapies3.4948 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsSMMTSummit Therapeutics2.6134 of 5 stars$17.32-0.2%$35.40+104.4%+573.6%$12.78B$700,000.00-61.85110News CoverageGMABGenmab A/S4.2091 of 5 stars$18.19-1.1%$41.33+127.2%-33.9%$12.04B$21.53B10.451,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.3519 of 5 stars$12.59+1.8%$17.00+35.1%-6.3%$10.51B$311.31B20.0424,800High Trading VolumeMRNAModerna4.259 of 5 stars$25.64+2.1%$59.00+130.1%-74.7%$9.91B$3.20B-2.763,900Gap DownVTRSViatris2.9677 of 5 stars$7.61-0.1%$10.50+38.0%-33.9%$9.08B$14.74B-10.2837,000News CoverageHigh Trading VolumeQGENQiagen3.483 of 5 stars$40.33+5.4%$47.71+18.3%+7.7%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S2.3142 of 5 stars$140.14-1.8%$204.64+46.0%+6.0%$8.50B$363.64M-19.741,017News CoveragePositive NewsGap DownROIVRoivant Sciences2.6317 of 5 stars$9.26-2.1%$17.50+89.0%-7.2%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies TEVA Alternatives ITCI Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives ASND Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRFS Stock Free GRFS Stock Alerts